Dr. Joseph Sarret

Dr. Joseph Sarret

Company: CohBar

Job title: Chief Executive Officer


Revealing Breakthrough Mitochondrial Science for IPF 5:30 pm

Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition. Discuss other potential antifibrotic indications for CB5138-3Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.